A Phase 2 interventional study of JX-594 recombinant vaccina GM-CSF and Best Supportive Care in Hepatocellular Carcinoma, Liver Cancer and HCC, sponsored by Jennerex Biotherapeutics. Completed at 38 sites in 7 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-07-08.
Sponsored by Jennerex Biotherapeutics · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 926 studies in Carcinoma, Hepatocellular with a site in United States — 160 open to participants now, 245 under way, 17 of them phase 3. Carcinoma, Hepatocellular · United States.
Among the 926 studies in Carcinoma, Hepatocellular with a site in United States, this one is the 156th largest by enrollment of the 775 interventional ones that give a count, is one of 24 that started in 2011, is one of 259 in phase 2, and was the 284th registered.
3,656 studies on the registry are indexed under Carcinoma, Hepatocellular; 1,068 are open to participants now.
Browse Carcinoma, Hepatocellular studies →160 of the 926 studies in Carcinoma, Hepatocellular with a site in United States are open now. Recruiting first, the newest first:
University of Arizona · Sites in United States
Ages 18–99
Abramson Cancer Center at Penn Medicine · Sites in United States
Ages 18+
University of Texas Southwestern Medical Center · Sites in United States
Ages 18+
University of Texas Southwestern Medical Center · Sites in United States
Ages 18+
Varian, a Siemens Healthineers Company · Sites in United States
Ages 21+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 743 Carcinoma, Hepatocellular studies recruiting now, 383 (52%) set no upper age limit and 253 (34%) stop at 75 or younger; 31 take children under 18; 31 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
926 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 336 · Phase 2 376 · Phase 3 66 · Phase 4 14
First in 1977; this study’s year is marked. 24 started in 2011.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 129 is above the median of 53 across 2,623 interventional studies indexed under Carcinoma, Hepatocellular.
Median enrollment 36 across the 775 interventional studies, 132 across the 121 observational. Of the 602 that completed or were terminated, 262 (44%) have results posted.
This tab as a report to print or save as PDF → With an account.
318 of 926 have an industry lead sponsor. The 10 most frequent:
Jennerex Biotherapeutics is the lead sponsor of 11 studies on the registry; none are open to participants now.
Jennerex Biotherapeutics has 4 studies filed under Carcinoma, Hepatocellular — fewer than ten, so there is no comparison to draw.
83 of the studies in Carcinoma, Hepatocellular with a site in United States that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT03654053Phase 3VA Office of Research and DevelopmentMulti-Center Study of the Effects of Simvastatin on Hepatic Decompensation and Death in Subjects Presenting With High-Risk Compensated Cirrhosis | 2026-12-31 |
| NCT06109272Phase 3AbbVieA Study to Assess the Dose, Adverse Events, and Change in Disease Activity of Livmoniplimab as an Intravenous (IV) Solution in Combination With Budigalimab as an IV Solution in Adult Participants With Hepatocellular Carcinoma (HCC) | 2027-01 |
| NCT05822752AbbVieStudy to Evaluate Adverse Events, and Change in Disease Activity, When Intravenously (IV) Infused With Livmoniplimab in Combination With IV Infused Budigalimab in Adult Participants With Hepatocellular Carcinoma (HCC) | 2026-11 |
| NCT01918683Abramson Cancer Center at Penn MedicineTACE With or Without SBRT as Bridging Therapy for Pre-transplant HCC Patients | 2026-12 |
| NCT04410302University of California, DavisPatient-Derived Xenografts to Reduce Cancer Health Disparities | 2026-12 |
Add all 83 to your calendar (.ics) → With an account.
Among the 926 studies in Carcinoma, Hepatocellular with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study is to determine whether JX-594 (Pexa-Vec) plus best supportive care is more effective in improving survival than best supportive care in patients with advanced Hepatocellular Carcinoma (HCC) who have failed sorafenib.
This Phase 2b, open-label, randomized, multi-center study is designed to evaluate the efficacy and safety of JX-594 (Pexa-Vec) in patients with advanced hepatocellular carcinoma (HCC) who have previously failed sorafenib treatment. Eligible patients are randomly assigned in a 2:1 ratio to receive either the experimental therapy (JX-594 plus Best Supportive Care [BSC]) or the control therapy (BSC alone).
Patients assigned to the experimental arm receive an initial intravenous (IV) infusion of JX-594 on Day 1. This is followed by intratumoral (IT) injections of JX-594 directly into viable liver tumors under imaging guidance on Day 8, Day 22, and Weeks 6, 12, and 18. These patients will also receive BSC, but active anti-cancer treatments are strictly prohibited. In contrast, patients in the control arm receive only Best Supportive Care (e.g., hydration, nutrition, pain management) at the treating physician's discretion without any study drug injections. Experimental or active anti-cancer therapies are not permitted in the control arm.
The primary objective of this study is to compare the Overall Survival (OS) between the two treatment arms. Secondary objectives include evaluating Time-to-Tumor Progression (TTP) and objective response rate based on mRECIST criteria for HCC. The study also evaluates Time-to-Symptomatic Progression (TSP), which is defined by changes in the FACT Hepatobiliary Symptom Index (FHSI-8) questionnaire and ECOG performance status. Additionally, the study assesses changes in Quality of Life (QoL) measured by EORTC and FACT-Hep questionnaires. Finally, overall safety and tolerability are closely monitored through the incidence and severity of Adverse Events (AEs) and Serious Adverse Events (SAEs) graded according to NCI CTCAE v4.03, along with clinical laboratory evaluations.
KEY Inclusion Criteria:
KEY Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Child-Pugh class
A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Patients on Arm A will receive 1 e9 pfu (plaque forming units) total dose of JX-594 (Vaccinia GM-CSF / TK-deactivated Virus) on each of six (6) treatments over 18 weeks.
Biological: JX-594 recombinant vaccina GM-CSF
Patients on the control arm (Arm B) will have best supportive care over 18 weeks.
Other: Best Supportive Care
Patients will be randomised 2:1 to Arm A or Arm B and will receive 6 treatments on days 1, 8, 22, week 6, week 12, and week 18 plus best supportive care as needed.
Patients will be randomised 2:1 to Arm A or Arm B and will receive best supportive care as needed.
Survival
Determine overall survival for patients receiving JX-594 plus best supportive care (Arm A) compared with those patients receiving best supportive care (Arm B) in patients with advanced hepatocellular carcinoma (HCC) who have failed sorafenib treatment.
Time frame: From randomization until death from any cause, assessed up to 21 months.
Time to Tumor Progression
Determine time-to-tumor-progression (TTP) for JX-594 + BSC compared with BSC alone based on mRECIST for HCC. Progression is defined as 2 consecutive time points with increases in the sum of the longest diameters (SLD) of viable target tumors of at least 20% for each time point.
Time frame: CT scan every six weeks until progression or death, assessed up to 21 months
Mean Percent Change From Baseline in Quality of Life (FACT-Hep Score)
Change in Quality of Life (QoL) over time based on the physical well-being and additional concerns domains of the Functional Assessment of Cancer Therapy - Hepatobiliary (FACT-Hep) Questionnaire. The FACT-Hep measures health-related quality of life in patients with hepatobiliary cancer. The item scores from these specific subscales are summed to compute a combined score. The combined score ranges from 0 to 100. Higher scores represent a better quality of life and a better outcome.
Time frame: Baseline to Visit 8 (Week 6 ) and Visit 11 (Week 12)
Overall Disease Control Rate (Tumor Response)
The overall disease control rate is defined as the percentage of patients achieving a Complete Response (CR), Partial Response (PR), or Stable Disease (SD) based on modified Response Evaluation Criteria in Solid Tumors (mRECIST) for Hepatocellular Carcinoma (HCC). Per mRECIST for HCC, CR is the disappearance of any intratumoral arterial enhancement in all target lesions; PR is a \>=30% decrease in the sum of the longest diameters (SLD) of viable target lesions; and SD is disease that does not qualify for either PR or progressive disease. Best response over all time points after Baseline was used.
Time frame: CT scan every 6 weeks until progression or death, assessed up to 21 months
Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)
Safety will be assessed by the number of adverse events (AEs) and serious adverse events (SAEs)
Time frame: Up to 28 days after the last dose of study drug, assessed up to 14 months.
Time-to-symptomatic-progression
Symptomatic progression is defined as a decrease of 4 points or more from Baseline in the FHSI-8 questionnaire (that was confirmed 3 weeks later), or a decrease in ECOG performance status to 4, or death.
Time frame: From randomization until symptomatic progression or death, assessed up to 21 months
Patients with advanced hepatocellular carcinoma (HCC) who had failed prior sorafenib treatment were recruited at 40 study centers across 7 countries (Canada, France, Germany, Hong Kong, South Korea, Taiwan, and the United States) between October 2011 and October 2013.
| Milestone | JX-594 + Best Supportive Care | Best Supportive Care |
|---|---|---|
| Started | 86 | 43 |
| Completed | 11 | 3 |
| Not completed | 75 | 40 |
| Withdrew: Withdrawal by subject | 8 | 27 |
| Withdrew: Adverse event | 13 | 4 |
| Withdrew: Physician decision | 22 | 3 |
| Withdrew: Death | 10 | 2 |
| Withdrew: Protocol violation | 0 | 1 |
| Withdrew: Other unspecified reasons | 14 | 2 |
| Withdrew: Intercurrent illness | 8 | 1 |
Determine overall survival for patients receiving JX-594 plus best supportive care (Arm A) compared with those patients receiving best supportive care (Arm B) in patients with advanced hepatocellular carcinoma (HCC) who have failed sorafenib treatment.
| months | JX-594 + Best Supportive Care | Best Supportive Care |
|---|---|---|
| Survival | 4.2 (3.3 to 5.4) | 4.4 (3.2 to 6.0) |
Determine time-to-tumor-progression (TTP) for JX-594 + BSC compared with BSC alone based on mRECIST for HCC. Progression is defined as 2 consecutive time points with increases in the sum of the longest diameters (SLD) of viable target tumors of at least 20% for each time point.
| months | JX-594 + Best Supportive Care | Best Supportive Care |
|---|---|---|
| Time to Tumor Progression | 1.8 (1.5 to 2.8) | 2.8 (1.5 to NA) |
Change in Quality of Life (QoL) over time based on the physical well-being and additional concerns domains of the Functional Assessment of Cancer Therapy - Hepatobiliary (FACT-Hep) Questionnaire. The FACT-Hep measures health-related quality of life in patients with hepatobiliary cancer. The item scores from these specific subscales are summed to compute a combined score. The combined score ranges from 0 to 100. Higher scores represent a better quality of life and a better outcome.
| Percent change (%) | JX-594 + Best Supportive Care | Best Supportive Care |
|---|---|---|
| Visit 8 (Week 6) | -10.2 ± 18.25 | 10.4 ± 50.88 |
| Visit 11 (Week 12) | -5.4 ± 20.15 | -3.6 ± 30.03 |
The overall disease control rate is defined as the percentage of patients achieving a Complete Response (CR), Partial Response (PR), or Stable Disease (SD) based on modified Response Evaluation Criteria in Solid Tumors (mRECIST) for Hepatocellular Carcinoma (HCC). Per mRECIST for HCC, CR is the disappearance of any intratumoral arterial enhancement in all target lesions; PR is a \>=30% decrease in the sum of the longest diameters (SLD) of viable target lesions; and SD is disease that does not qualify for either PR or progressive disease. Best response over all time points after Baseline was used.
| Percentage (%) | JX-594 + Best Supportive Care | Best Supportive Care |
|---|---|---|
| Overall Disease Control Rate (Tumor Response) | 13 (7 to 22) | 19 (8 to 33) |
Safety will be assessed by the number of adverse events (AEs) and serious adverse events (SAEs)
| participants | JX-594 + Best Supportive Care | Best Supportive Care |
|---|---|---|
| Patients with at least one Adverse Event (AE) | 84 | 21 |
| Patients with at least one Serious Adverse Event (SAE) | 50 | 10 |
Symptomatic progression is defined as a decrease of 4 points or more from Baseline in the FHSI-8 questionnaire (that was confirmed 3 weeks later), or a decrease in ECOG performance status to 4, or death.
| months | JX-594 + Best Supportive Care | Best Supportive Care |
|---|---|---|
| Time-to-symptomatic-progression | 2.5 (1.9 to 2.9) | 2.0 (1.5 to 3.5) |
Collected over All-Cause Mortality monitored/assessed up to 21 months. Adverse Events monitored/assessed from informed consent signature through 28 days after the most recent study treatment or Week 18, assessed up to 14 months.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| JX-594 + Best Supportive Care | 17/86 (19.8%) | 50/84 (59.5%) | 84/84 (100%) |
| Best Supportive Care | 6/43 (14%) | 10/25 (40%) | 21/25 (84%) |
| Event | JX-594 + Best Supportive Care | Best Supportive Care |
|---|---|---|
| Hepatic failureHepatobiliary disorders | 7/84 | 2/25 |
| PyrexiaGeneral disorders | 7/84 | 0/25 |
| Abdominal painGastrointestinal disorders | 4/84 | 2/25 |
| Back painMusculoskeletal and connective tissue disorders | 1/84 | 2/25 |
| Gastric varices haemorrhageGastrointestinal disorders | 1/84 | 2/25 |
| Malignant neoplasm progressionNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/84 | 2/25 |
| HypotensionVascular disorders | 6/84 | 1/25 |
| Oesophageal varices haemorrhageGastrointestinal disorders | 5/84 | 1/25 |
| Pulmonary embolismRespiratory, thoracic and mediastinal disorders | 5/84 | 0/25 |
| AstheniaGeneral disorders | 4/84 | 1/25 |
| Event | JX-594 + Best Supportive Care | Best Supportive Care |
|---|---|---|
| PyrexiaGeneral disorders | 67/84 | 3/25 |
| ChillsGeneral disorders | 44/84 | 1/25 |
| Abdominal painGastrointestinal disorders | 32/84 | 8/25 |
| Decreased appetiteMetabolism and nutrition disorders | 31/84 | 3/25 |
| NauseaGastrointestinal disorders | 30/84 | 4/25 |
| AscitesGastrointestinal disorders | 21/84 | 8/25 |
| HypotensionVascular disorders | 24/84 | 3/25 |
| Rash pustularInfections and infestations | 24/84 | 0/25 |
| AnaemiaBlood and lymphatic system disorders | 22/84 | 4/25 |
| FatigueGeneral disorders | 22/84 | 2/25 |
Intent-to-Treat (ITT) Population
| Age, Continuous(Years) | JX-594 + Best Supportive Care | Best Supportive Care | Total |
|---|---|---|---|
| Mean | 60.2 ± 10.70 | 54.5 ± 12.10 | 58.3 ± 11.46 |
| Sex: Female, Male(Participants) | JX-594 + Best Supportive Care | Best Supportive Care | Total |
|---|---|---|---|
| Female | 14 | 10 | 24 |
| Male | 72 | 33 | 105 |
| Race (NIH/OMB)(Participants) | JX-594 + Best Supportive Care | Best Supportive Care | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 |
| Asian | 52 | 26 | 78 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 2 | 1 | 3 |
| White | 30 | 15 | 45 |
| More than one race | 0 | 0 | 0 |
| Unknown or Not Reported | 2 | 1 | 3 |
| Ethnicity (NIH/OMB)(Participants) | JX-594 + Best Supportive Care | Best Supportive Care | Total |
|---|---|---|---|
| Hispanic or Latino | 3 | 2 | 5 |
| Not Hispanic or Latino | 83 | 41 | 124 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Region of Enrollment(Participants) | JX-594 + Best Supportive Care | Best Supportive Care | Total |
|---|---|---|---|
| South Korea | 39 | 19 | 58 |
| United States | 13 | 10 | 23 |
| Germany | 13 | 0 | 13 |
| France | 7 | 7 | 14 |
| Canada | 7 | 2 | 9 |
| Taiwan | 6 | 5 | 11 |
| China | 1 | 0 | 1 |
Ran from Oct 2011 to primary completion in Oct 2013, 23 months.
Results were first posted in Jul 2026, 12 years 9 months after primary completion.
Of 80 industry-sponsored phase 2 interventional studies under Carcinoma, Hepatocellular, half reached primary completion within 38 months of starting (the median), counting those still running; a quarter within 23 and three quarters within 50. This study's 23 months is below that.
Counting every sponsor, half of 432 studies reached it within 43 months; a quarter within 30 and three quarters within 71.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: JX-594
Jennerex Biotherapeutics